AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01786824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed.
Study NCT01786824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronarography
Description: All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
Study NCT01786824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronarography
Description: All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
Study NCT02161328 — intervention group
Intervention type: OTHER
Intervention: EIT belt
Study NCT03525574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study NCT03525574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT01565200 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: T-DM1
Description: 3.6 mg/kg iv every 3 weeks
Study NCT01565200 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 89Zr-trastuzumab
Description: Injection of 89Zr-trastuzumab for HER2 imaging
Study NCT00472186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
Study NCT00472186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will also be administered based on weight.
Study NCT01254565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously (IV) at the end of hemodialysis
Study NCT01254565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously at the end of hemodialysis
Study NCT03989635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAW039
Description: QAW039 450mg
Study NCT03989635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 450mg
Study NCT03030547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear activity monitor
Description: Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
Study NCT03030547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseWear activity monitor
Description: Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
Study NCT02917044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Fibrillation Ablation
Description: Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
Study NCT02917044 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheters used to isolate pulmonary veins
Description: Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
Study NCT02917044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheters used to isolate pulmonary veins
Description: Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
Study NCT02917044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation Ablation with HD mapping to isolate PVs
Description: Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
Study NCT02917044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmia HD mapping
Description: Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
Study NCT00505167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Patients randomized to receive either memantine or donepezil
Study NCT04409535 — intervention group
Intervention type: OTHER
Intervention: WHOQOL-BREF survey
Description: Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
Study NCT00310206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
Study NCT00310206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
Study NCT01644526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoaccess Valve System
Description: Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
Study NCT00877955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam sublingual tablet commercial
Description: 0.5 mg sublingual tablet, single dose
Study NCT00877955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam sublingual tablet test
Description: 0.5 mg tablet, single dose
Study NCT03185806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puncture and drainage
Description: The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
Study NCT03634033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MiCAP with IF (Main Study)
Description: Sites will conduct MiCAP strategies described as follows. Relationship Building; Assess readiness to implement of the site; Internal Facilitator (IF) Champion Coalition Building, which will include IFs training in CAPABLE and facilitation and online IF coalition meetings; Facilitation by the IF, which will include training the clinicians, reviewing home visits with the clinician to assure CAPABLE was provided; IF developing a clinical team for implementation of CAPABLE and leading interdisciplinary coordination of individual beneficiary care; Intervention and implementation strategy fidelity data will be placed in a dashboard for audit and provided to IFs. IFs will use the data to provide feedback to clinicians; and develop action plans for improvement in training or care.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently.
Study NCT03634033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MiCAP with IF and EF (Main Study)
Description: Sites will conduct MiCAP strategies described above in MiCAP with IF with an addition of External Facilitation. Centralized Oversight will be conducted by External Facilitators. External Facilitators will train in facilitation. The work of the External Facilitators will be tailored (i.e., type of discipline) to each site's needs. Intervention and implementation strategy fidelity data will be placed in a dashboard and will be provided to External Facilitators. External Facilitators will use the data to provide feedback to Internal Facilitators; and develop action plans for improvement in site clinician training or beneficiary care as needed.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently.
Study NCT03634033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MiCAP with IF and Caregiver Engagement (Administrative Supplement)
Description: A pilot study to examine use of informal caregiver engagement to provide CAPABLE to beneficiaries with Alzheimer's Disease or other Dementia using MiCAP with Internal Facilitation (implementation strategies from the (Main Study). External facilitator will be Champion, clinician, and an early adopters of CAPABLE.
Study NCT01338961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic CPB
Description: Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
Study NCT02762552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial-holter monitoring
Description: Transcranial holter with an 4 hour-recording
Study NCT02559791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 3ml/kg once monthly for 4 months
Study NCT02559791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo once monthly for 2 months
Study NCT00654875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren supplied in 150 mg and 300 mg tablets.
Study NCT00654875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren matching 150 and 300 mg tablets
Study NCT01801358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
Study NCT01801358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
Study NCT00505167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Patients randomized to receive either memantine or donepezil
Study NCT01074749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accent Pacemaker
Description: Implantation of pacemaker
Study NCT02585271 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transanal decompression tube
Description: 22 Fr transanal decompression tube
Study NCT02585271 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stent
Description: self-expandable colorectal nitinol alloys stent
Study NCT01834716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic vs. Non-Aerobic exercise
Study NCT01930344 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Laparoscopic visual system
Description: Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
Study NCT01930344 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2D Laparoscopic visual system
Description: Standard 2D HD Laparoscopic Visual System
Study NCT04257162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tumor and Blood sample collection
Description: This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study
Study NCT00583882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine change of central venous catheters
Description: Changeing CVCs on a regular basis to decrease infection rate.
Study NCT04530591 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
Study NCT04530591 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device.
Study NCT00093418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT00058084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00058084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT00058084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT02750007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004
Study NCT00003910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
Study NCT00003910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
Study NCT00003910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
Study NCT00697034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
Study NCT05475587 — intervention group
Intervention type: OTHER
Intervention: Routine care
Description: Both two groups received the same routine care.
Study NCT03333902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: QLB, quadratus lumborum block.
Study NCT03333902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB
Description: QLB, quadratus lumborum block.
Study NCT03333902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia (PCA)
Description: Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
Study NCT03333902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient controlled analgesia (PCA)
Description: Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
Study NCT02681757 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: triple antibiotic ointment dressing
Description: used for control group under soft cast
Study NCT02681757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel Ag
Description: used for variable/experimental group under soft cast
Study NCT04339803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation intervention
Description: we use lower limb mirror therapy after stroke for two weeks
Study NCT02634034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: NK-104-CR 8 mg
Description: NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
Study NCT02634034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: Pitavastatin IR 4 mg
Description: Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
Study NCT02634034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: Pitavastatin IR 8 mg
Description: Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
Study NCT00493233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)
Description: Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period.
Study NCT00493233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: main antipsychotic medication and placebo
Description: The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician.
Study NCT01760746 — intervention group
Intervention type: OTHER
Intervention: Injection of Avastin / Lucentis, sampling aqueous humour
Description: Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays.
Study NCT03663777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Description: Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
Study NCT03663777 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
Study NCT01513811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol electrolyte solutions
Description: Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
Study NCT01513811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride and Polyethylene glycol electrolyte solutions
Description: Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
Study NCT01513811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itopride and polyethylene glycol electrolyte solutions
Description: Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
Study NCT00881439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Oral, 300 mg, once daily, 6 months
Study NCT00881439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo once daily, 6 months
Study NCT00176436 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet support group
Description: Diet support group weekly and exercise sessions 3 times/week, placebo medication
Study NCT00176436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group counseling and exercise
Description: Support group weekly and exercise sessions 3 times/week for 24 weeks